FEMASYS INC (FEMY): Nasdaq/NYSE listing notice — Femasys receives Nasdaq delisting notice over bid price below $1.00

FEMASYS INC

Nasdaq notified Femasys on June 1, 2023 of non-compliance with Minimum Bid Price Requirement (closing bid below $1.00 for 30 consecutive business days).
Company has 180 calendar days, until November 28, 2023, to regain compliance by closing at $1.00+ for at least ten consecutive business days.
If not compliant by Nov. 28, 2023, may qualify for an additional 180-day period if it meets other Nasdaq initial listing standards.
Femasys may consider a reverse stock split to cure the deficiency; no immediate impact on listing or trading of FEMY shares.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

FEMASYS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

June 1, 2023, Femasys Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market. The Company has 180 calendar days, or until November 28, 2023, to regain compliance with the Minimum Bid Price Require

View on SEC.gov

Browse all listing & compliance notices →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-028114

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.